News

Proton partners international brings proton beam therapy to England

30th July 2015: Proton Partners International Limited today unveiled the site of the first Proton Beam Therapy cancer treatment centre to be built in England.

The centre will be the second to be built by Proton Partners International in the UK. It will be situated on the Earth Balance wellness suite in Bomarsund, Northumberland, and will operational by early 2017.

Earlier this month Proton Partners announced that it had already started work on its first site in Newport, Wales. The third centre will be in London. Each centre will be able to treat up to 700 patients annually.

Read more

Gordon McVie, Chairman of Proton Partners International Ltd, said: “Our goal is to herald a new era of cancer care provision in the UK, bringing the first high energy Proton Beam Therapy centres to the UK and therefore unveiling our second site today marks another significant milestone.

“It is estimated that around 10% of patients who receive radiotherapy would be better treated by Proton Beam Therapy. Across the world Proton Beam Therapy has been shown to deliver significant results for patients, especially in lowering side effects. The sooner we can start treating patients with Proton Beam Therapy in the UK the better.”

Speaking at the launch, Councillor Grant Davey, Leader of Northumberland County Council, said: “We are delighted Northumberland has been chosen as the first place in England to be able to provide high energy Proton Beam Therapy. This is not only good news for the county – it will provide a great economic boost to the whole region and highlight our commitment as a place to invest for the future.”

Mike Moran, Chief Executive Officer of Proton Partners International Ltd., added: “The new centres to be opened by Proton Partners will not just benefit private patients, but also hope to treat NHS patients in need of more highly specialised cancer care. We are working with global leaders in Proton Beam Therapy – our centres will be equipped with the best technology there is.”

The work is part of a new programme of developments by the Earth Balance charity which is opening the wellness site to help meet the needs of current and future generations.

Chair of Earth Balance, Alan Rutherford said: “We are delighted that Proton Partners International are coming to the site and we are working hard with local healthcare partners, energy partners, health and wellbeing partners and the local community to ensure that the training and care opportunities are meeting local needs.”

IBA (Ion Beam Applications), the world’s leading provider of proton therapy solutions for the treatment of cancer, has been selected to install its single-room proton therapy system, Proteus®ONE.

Philips has been appointed to deliver software and technology tools including Philips’ Pinnacle Treatment Planning which delivers an intuitive planning environment that simplifies workflow. Philips will also provide big bore CT scanners at each centre and a PET CT in the Newport centre.

ENDS

Further information:

Contact

Ramsay Smith, Media House 07788 414856 ramsay@mediahouse.co.uk

Sophie Watson, Media House 0207 710 0020 / 07554 005794 sophie@mediahouse.co.uk

About Proton Partners International Limited

Proton Partners International is a private limited company, registered in Wales. The company was formed following discussions between Professor Karol Sikora, former head of the World Health Organisation’s cancer programme, Professor Sir Chris Evans, the leading life sciences entrepreneur, and Neil Woodford, founding partner of Woodford Investment Management. Institutional and private investors have committed to almost £100m equity finance in the company.

Professor Gordon McVie, Senior Consultant at the European Institute of Oncology, which partners the Italian Hadron Centre in Pavia, has been appointed chairman and Professor Karol Sikora is chief medical adviser to the company.

For more information on Proton Partners, please visit: http://proton-int.com/

About Proton Beam Therapy

Proton beam therapy is a highly-targeted type of radiotherapy that can treat hard-to-reach cancers, such as spinal tumours (chordomas), with a lower risk of damaging the surrounding tissue and causing side effects.

Proton Partners International Chief Executive Officer Mike Moran (centre) and Chairman of Earth Balance Alan Rutherford (left) with Northumberland County Council Leader Cllr Grant Davey at the site of the new proton beam therapy centre in Northumberland.

The site of the new pioneering proton beam therapy centre in Bomarsund, Northumberland which will be constructed and operational by 2017.

Share via Twitter

Share via LinkedIn

Proton partners international chosen to develop and operate UAE’s first proton beam therapy centre

July 17th 2015: Proton Partners International Ltd has been chosen to provide the United Arab Emirates with its first Proton Beam Therapy centre.

Proving that they are not only leading the way for Proton Beam Therapy in the UK but also abroad, Proton Partners has been selected to develop and operate the Abu Dhabi Proton Centre (ADPC) in Abu Dhabi with SBK Holding LLC and Albans Partners General Trading LLC.


Read more

Mike Moran MBE, CEO of Proton Partners International Ltd, said: “I am delighted to be invited to the UAE to support the development of the Abu Dhabi Proton Centre (ADPC).

“Proton Partners International is the United Kingdom’s leading developer of Proton Beam Therapy facilities having recently announced the development of three centres across the UK. We work with world leading technology partners such as Philips, IBA, ORCA and MEI Healthcare and I am thrilled that they will also support us in the development of the ADPC.

“By bringing Proton Beam Therapy to the people of UAE, His Highness Dr. Sheikh Sultan Bin Khalifa Al Nahyan has shown a vision for the future of healthcare in the country and I very much look forward to supporting his aim of delivering the most advanced cancer treatments to the people of the UAE.”

Professor Karol Sikora, Chief Medical Officer of Proton Partners International, said: “It is fantastic that His Highness’ foresight will lead to the first installation of sophisticated proton delivery technology in the Middle East. I am confident that by creating a global network of proton centres connecting leading institutes in Britain with Abu Dhabi is the best way forward.

“Proton therapy is suitable for around 10% of patients receiving conventional radiotherapy and delivers a much more precise dose distribution, sparing normal tissue and so serious long term toxicity. We are confident that with the skills and enthusiasm we’ve seen in Abu Dhabi, we can deliver this project within the next two years.  Cancer incidence is rising dramatically globally and more innovation is needed to deal with this disease. We envisage this development will put the UAE in the frontline of cancer treatment and research.”

Gordon Baltzer, Chairman of the MEI Healthcare Group, said: “Our organisation is truly excited about this opportunity to bring innovative healthcare technology and expertise to patients in the United Arab Emirates.

“The creation of this comprehensive cancer center including innovative proton therapy capability, will ensure access to world class oncology services in the UAE.”

David Knott, Chief Executive Officer for the MEI Healthcare Group, added:  “This innovative and proven team of healthcare partners possess the required expertise and capability to ensure the successful development, construction, and operation of this state-of-the-art oncology program.”

SBK Holding LLC is the Holding Company of His Highness Dr. Sheikh Sultan Bin Khalifa Bin Zayed Al Nahyan, Advisor to the President of the United Arab Emirates, the eldest son of His Highness Sheikh Khalifa Bin Zayed Al Nahyan, President of the United Arab Emirates, Supreme Commander of the UAE Armed Forces, and Ruler of Abu Dhabi.

SBK Holding has a range of companies that serve a broad cross-section of industries not only in the Gulf region but also globally. SBK Holding employs 10,000 employees in the UAE and with its substantial international investments the company has a workforce that reaches all corners of the world.

ENDS

Further information:
Sophie Watson / Gary McQueen
Media House International Ltd.
0207 710 0020 / 0141 220 6040

About Proton Therapy
Proton Therapy is considered the most advanced and targeted cancer radiotherapy treatment due to its superior dose distribution and fewer side effects. Protons deposit the majority of their effective energy within a precisely controlled range, directly within the tumor, sparing healthy surrounding tissue. Higher doses can be delivered to the tumor without increasing the risk of side effects and long-term complications, thereby improving patient outcomes and quality of life. Today, more than half of all proton therapy clinical facilities worldwide are equipped with IBA systems. This includes 18 proton therapy centers currently in operation and 19 additional centers under development.

While proton therapy today represents less than 1% of radiotherapy treatments, studies estimate that more than 17% of patients treated by radiotherapy would benefit from being treated by this technique.

About Proton Partners International Limited
Proton Partners International is a private limited company, registered in Wales. The company was formed following discussions between Professor Karol Sikora, former head of the World Health Organisation’s cancer programme, Professor Sir Chris Evans, the leading life sciences entrepreneur, and Neil Woodford, founding partner of Woodford Investment Management. Institutional and private investors have committed to almost £100m equity finance in the company.

Professor Gordon McVie, Senior Consultant at the European Institute of Oncology, has been appointed chairman, Professor Karol Sikora is Chief Medical Advisor and, one of the Founders, Mike Moran MBE has been appointed as the Chief Executive Officer.

About IBA
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The Company is the worldwide technology leader in the field of proton therapy, the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full scale proton therapy centers as well as compact, single room systems.  In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry.

Headquartered in Belgium and employing about 1100 people worldwide, IBA has installed systems across the world, from Europe and the US and to the emerging markets.  IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

About Philips
Royal Philips is a diversified health and well-being company, focused on improving people’s lives through meaningful innovation in the areas of Healthcare, Consumer Lifestyle and Lighting. Headquartered in the Netherlands, Philips posted 2014 sales of EUR 21.4 billion and employs approximately 108,000 employees with sales and services in more than 100 countries.

The company is a leader in cardiac care, acute care and home healthcare, energy efficient lighting solutions and new lighting applications, as well as male shaving and grooming and oral healthcare.

About MEI Healthcare Group
MEI Healthcare Group is a U.S. based healthcare strategy and development company that provides vertically integrated solutions to the global healthcare community. MEI has more than 40 years of experience in the turn-key planning, development, financing and commercialization of healthcare strategies across a variety of service lines.   MEI’s service portfolio includes project development, equipment selection, financial modelling, advisory and consultative services, and facility management services.  MEI Healthcare Group is led by Gordon Baltzer, Chairman and David Knott, Chief Executive Officer.

Share via Twitter

Share via LinkedIn

Reneuron Success Boosts Wales Life Sciences Fund

London, Friday 10 July 2015 – Professor Sir Christopher Evans, chairman of Arthurian Life Sciences Ltd, said today that it is ‘pivotal’ that Wales continues to aggressively develop its life sciences sector following the ‘hugely encouraging’ fundraising for ReNeuron Group plc.

ReNeuron Group plc, a leading UK-based clinical-stage cell therapy company, today announced that it had raised £68.4million ($100m) through a conditional placing with new and existing investors in the UK, which marks a significant step towards improving the therapeutic programmes on offer.

Read more

 

Arthurian were the first of the original investors in ReNeuron Group plc, committing a further £5million to help lead the latest and significant investment round of £68.4million. Other existing investors – Woodford, Aviva and Abingworth – also committed substantial amounts to the fundraise. Several new institutional investors from the UK and USA also joined in this landmark fundraise for the company.

Sir Chris Evans said: “The ReNeuron fundraising has been very successful and hugely encouraging, not just for the Company but for life sciences in Wales as well.
“Wales has made some very significant strides in developing its life sciences sector through the establishment of the Wales Life Sciences Fund and it is pivotal that Wales continues to keep aggressively pursuing these opportunities.

“This is a momentous achievement for ReNeuron – this fundraise underpins one of the world’s most exciting novel stem-cell therapeutic portfolios. These new funds will be used to further progress ReNeuron’s CTX therapies in trials for Stroke and Critical Limb Ischaemia, to initiate new trials with the unique hRPC stem cell formulations for Retinal Blindness and to rapidly progress the Company’s new breakthrough platform technology in Exosome Nanomedicines for Cancer and other future applications.

“It is a hugely significant development for the future of cell-based therapies across the globe. The future looks bright and very exciting for this world leading stem-cell company and I’m delighted to have been associated with it from the very beginning.”

Sir Chris’ Arthurian Welsh Life Sciences Fund has shot up in value, going from strength to strength in under 15 months from a standing start as significant product announcements are made and new investments are sealed in an ever expanding pipeline of very exciting biotech and healthcare businesses.

The Fund is about to conclude two more investments in July, establishing a portfolio of 10 companies valued over £600million and having attracted in excess of £250million new co- investment in under 15 months. The Fund is running at a 48% IRR and the Team are evaluating several future transactions from a deal flow pool in excess of 450 new life sciences businesses from around the world.

ENDS
Notes to Editors:
Media contact
Ramsay Smith at Media House International on 020 7710 0020 or ramsay@mediahouse.co.uk
Sophie Watson at Media House International on 020 7710 0020 or sophie@mediahouse.co.uk

About Arthurian Life Sciences
Arthurian Life Sciences Ltd was specifically established by Europe’s leading biotech entrepreneur Professor Sir Chris Evans OBE to apply to provide management services to the Wales Life Sciences Investment Fund. Arthurian boasts a vastly experienced, internationally renowned Board of Directors and investment team comprised of individuals from the public and private Life Sciences sector and from the world of international fund management, business, commerce and government. The Arthurian team currently manages, advises and consults to billions of pounds of assets in private equity and traditional investments.

Share via Twitter

Share via LinkedIn

Proton Partners Secures Newport Site

logo-insider-media-ltd

Published 3rd July 2015.

Proton Partners International has secured a site in Newport for the location of its first high energy proton beam therapy cancer treatment centre.

In April 2015, Proton Partners International secured £100m in equity finance with Sir Chris Evans and Arthurian Life Science investing in the newly formed company through the Wales Life Sciences Investment Fund, established by the Welsh Government.

The facility will be located at the Celtic Springs Business Park. Renovation of the site will begin next week and the centre is due to be operational next year.

Read more

The Newport centre will be the first of three planned proton beam therapy sites in the UK. The others will be in Northumberland and London with additional sites identified in Liverpool and Birmingham.

In April 2015, Proton Partners International secured £100m in equity finance with Sir Chris Evans and Arthurian Life Science investing in the newly formed company through the Wales Life Sciences Investment Fund, established by the Welsh Government.

Mike Moran, chief executive officer of Proton Partners International, said: “We are delighted to have completed the acquisition of the site and work will begin immediately.

“We are working very closely with the Welsh Government and the Wales Life Sciences Fund to create what will be a step change in cancer treatment in the UK.”

Proton has appointed the company Ion Beam Applications to install its single-room proton therapy system at the facility, while Philips has been appointed to supply software and technology tools as well as a CT scanner.